Canada's Med BioGene to File for US IPO | GenomeWeb

NEW YORK (GenomeWeb News) – Canadian molecular diagnostics firm Med BioGene said yesterday that it intends to file for an initial public offering "as soon as possible" in the US to support development and commercialization of its gene expression-based assay for early-stage non-small-cell lung cancer.

MBI, based in Vancouver, BC, said that it has retained the services of Rodman & Renshaw as lead underwriter for the IPO, and will float an unspecified number of common shares on the Nasdaq Capital Market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.